Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$41 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
2
Div. Yield
0 %
Debt to Equity
--
Book Value
$4.6
EPS
$-4
Face value
--
Shares outstanding
8,611,428
CFO
$-124.31 Mln
EBITDA
$-158.28 Mln
Net Profit
$-171.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| -39.4 | 21.1 | -39.4 | -45.1 | -21.0 | -30.2 | -39.9 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| -37.5 | 7.2 | 66.5 | -66.9 | 68.4 | -39.5 | 53.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
|
5.4 | 40.6 | 0.0 | -34.8 | -- | -62.7 | -- | 0.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug... candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104 Read more
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Atossa Genetics Inc (ATOS) is $5.37 (NASDAQ) as of 02-Apr-2026 18:43 EDT. Atossa Genetics Inc (ATOS) has given a return of -20.98% in the last 3 years.
Since, TTM earnings of Atossa Genetics Inc (ATOS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.15
|
0.13
|
|
2024
|
-0.31
|
0.11
|
|
2023
|
-3.66
|
1.21
|
|
2022
|
-0.17
|
0.04
|
|
2021
|
-0.66
|
0.10
|
The 52-week high and low of Atossa Genetics Inc (ATOS) are Rs 19.35 and Rs 3.76 as of 05-Apr-2026.
Atossa Genetics Inc (ATOS) has a market capitalisation of $ 41 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Atossa Genetics Inc (ATOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.26
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.